Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
10934 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 6003
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| ABO2203 Injection NCT07072169 · A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Rela… | Sclérose en plaques | Immunomodulation · Thérapie génique | Phase 1 | RECRUITING | The purpose of this study is to evaluate the safety, tolerability, pharmac… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| anti-CD19 UCAR-NK cells NCT05570188 · Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematolog… | Sclérose en plaques | Immunomodulation | Phase 1/2 | WITHDRAWN | It is a single-center, open-labeled, single-arm, non-randomized investigat… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| CD19-BCMA dual nanobody based CAR-T Cells NCT07451236 · CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | This is an early-stage, open-label clinical study of CD19-BCMA dual nanobo… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| CD45RA-depleted peripheral blood mononuclear cells NCT02942173 · CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-de… | Sclérose en plaques | Thérapie cellulaire | Phase 2/3 | COMPLETED | The purpose of this prospective randomized study is to determine whether i… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| huCART19-IL18 NCT04684563 · huCART19-IL18 in CD19+ Cancers | Sclérose en plaques | À vérifier | Phase 1 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and feasibility of huC… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:25 | Détail |
| Calaspargase Pegol NCT05581030 · CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | The purpose of the study is to evaluate the safety and tolerability of the… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| CD19 CAR-T NCT04626726 · Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Tra… | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is an open, single-arm, phase I clinical study to evaluate efficacy a… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Chimeric Antigen Receptor T-Cell Therapy NCT06854159 · Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 2 | RECRUITING | This phase II trial tests how well odronextamab works before and after sta… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Cyclophosphamide NCT03505762 · Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B… | Sclérose en plaques | À vérifier | Phase 2 | ACTIVE_NOT_RECRUITING | This randomized phase II trial studies how well paclitaxel with or without… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Ofatumumab NCT01555541 · Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologou… | Sclérose en plaques | Remyélinisation · Thérapie cellulaire | Phase 2 | COMPLETED | This is an observational cross-sectional study of Ocrelizumab or Ofatumuma… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| R-CHOP NCT02054559 · ASPIRE — R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL | Sclérose en plaques | Immunomodulation | Phase 3 | WITHDRAWN | To compare the efficacy and safety of chemotherapy alone and combined moda… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| ST-067 NCT04787042 · Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This is a multiphase, multicenter study, which includes a Phase 1a open-la… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:24 | Détail |
| Aminophylline NCT07348510 · Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Car… | Sclérose en plaques | À vérifier | Non applicable | RECRUITING | This safety study is the first in a series of studies testing the applicat… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Aminophylline NCT01250496 · ASSUAGE — Study With Aminophylline to Attenuate of the Side Effects of Regadenos… | Sclérose en plaques | À vérifier | Phase 4 | TERMINATED | This safety study is the first in a series of studies testing the applicat… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Ivacaftor NCT02310789 · (Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The… | Sclérose en plaques | À vérifier | Non applicable | COMPLETED | Clinical studies of lumacaftor + ivacaftor (combo therapy) produced better… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Theophylline ER NCT03984188 · Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated… | Sclérose en plaques | À vérifier | Phase 3 | COMPLETED | Pseudohypoparathyroidism is a genetic disorder with limited treatment opti… À vérifier | ClinicalTrials.gov 2026-11-15 04:38:19 | Détail |
| Belatacept 250 Milligram Intravenous Powder for Solution NCT05562869 · BELASBRIDGE — Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplan… | Maladie rénale chronique | À vérifier | Phase 3 | RECRUITING | Calcineurin inhibitors (CNI) remain the standard treatment in renal transp… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
| Finerenone NCT07841015 · FINE-IMSS-MX — A Study to Learn More About How Well Finerenone Works in Real-wor… | Maladie rénale chronique | Traitement symptomatique | À vérifier | NOT_YET_RECRUITING | This study is a multicenter, double-blind, randomized, placebo-controlled… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
| KDSTEM Inj. NCT06071143 · Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease | Maladie rénale chronique | Thérapie cellulaire | Phase 1 | COMPLETED | A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
| Medium Cut-Off Dialyzer for Expanded Hemodialysis NCT07936942 · Quality of Life and Uremic Toxins in HDx | Maladie rénale chronique | À vérifier | Non applicable | COMPLETED | Expanded hemodialysis (HDx) is a dialysis treatment designed to improve th… À vérifier | ClinicalTrials.gov 2026-11-15 04:37:57 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4910
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| MRI-defined compression stages and postoperative neurological recover… spinal cord MRI follow-up · PMID 42431540 | Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Neurological impairment in thoracic spinal tuberculosis is often related to complex inflammatory and compressive lesion… | International journal of infectious diseases : IJID :… 2026-07-12 19:40:34 | Source |
| HERV Dysregulation in a Case of Myalgic Encephalomyelitis and Multipl… GNbAC1 Monoclonal Antibody · PMID 40430026 | Sclérose en plaques | Ralentissement de la progression · Traitement symptomatique | Publication | PubMed | Voir la publication source This article summarizes the case of 30-year-old male diagnosed with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome… | International journal of molecular sciences 2026-07-12 19:40:26 | Source |
| West Nile Neuroinvasive Disease: Current Management, Emerging Therapi… Teriflunomide HMR1726 · PMID 42431607 | Sclérose en plaques | Neuroprotection · Traitement symptomatique | Publication | PubMed | Voir la publication source West Nile virus (WNV) is a climate-sensitive, mosquito-borne flavivirus that has become endemic in Europe, with Italy,… | Reviews in medical virology 2026-07-12 19:40:24 | Source |
| Antioxidant Nanozymes: From Rational Design to Biomedical Application… CNM-Au8 · PMID 42381982 | Sclérose latérale amyotrophique · Cancer | Remyélinisation indirecte / réparation · Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Antioxidant nanozymes regulate reactive oxygen species homeostasis by mimicking the core catalytic functions of natural… | Research (Washington, D.C.) 2026-07-12 19:40:18 | Source |
| Nanomedicine in 2026: Illustrative Quantitative Analyses of EPR Heter… CNM-Au8 · PMID 42311422 | Sclérose latérale amyotrophique · Cancer | Remyélinisation indirecte / réparation · Neuroprotection | Publication | PubMed | Voir la publication source 2026 is a turning point for nanomedicine, marking the field's transition from decades of preclinical promise toward tan… | International journal of nanomedicine 2026-07-12 19:40:18 | Source |
| Age-associated B-cells across the rheumatoid arthritis continuum: fro… Risk Factors in Early Multiple Sclerosis · PMID 42428157 | Lupus · Sclérose en plaques | Immunomodulation | Publication | PubMed | Voir la publication source Age-associated B cells (ABCs) are a B-cell subset with distinct transcription and functional properties. Their function… | Frontiers in aging 2026-07-12 19:40:12 | Source |
| Lifetime exposure to shift work and risk of multiple sclerosis: retro… Risk Factors in Early Multiple Sclerosis · PMID 42431827 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Multiple sclerosis (MS) is an autoimmune disease with complex aetiology involving genetic, environmental and lifestyle… | Occupational and environmental medicine 2026-07-12 19:40:12 | Source |
| Aerobic conditioning and ginsenoside modulation modify molecular resi… Ginseng · PMID 42435534 | Sclérose en plaques | À vérifier | Publication | PubMed | Voir la publication source Hippocampal aging is characterized by early cognitive decline, disrupted redox homeostasis, and shifts in amyloid proce… | Biomedicine & pharmacotherapy = Biomedecine & pharmaco… 2026-07-12 19:40:11 | Source |
| Ginseng marc-derived low-molecular-weight neutral glucan SN-GOS ameli… Ginseng · PMID 42435659 | Sclérose en plaques | Remyélinisation indirecte / réparation · Immunomodulation | Publication | PubMed | Voir la publication source Although ginseng marc has been routinely discarded as a waste, it still contains considerable amounts of bioactive comp… | Carbohydrate research 2026-07-12 19:40:11 | Source |
| Beyond motor symptoms: efficacy of pharmacotherapies on motor, functi… Pridopidine · PMID 42162688 | Sclérose en plaques · Sclérose latérale amyotrophique · Sclérose laté… | Traitement symptomatique | Publication | PubMed | Voir la publication source Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor, neuropsychiatric, cogniti… | European journal of pharmacology 2026-07-10 11:50:03 | Source |
| Pridopidine Protects ALS Patient-Derived Neural Progenitor Cells via… Pridopidine · PMID 42074133 | Sclérose latérale amyotrophique | Remyélinisation indirecte / réparation · Thérapie cellulaire | Publication | PubMed | Voir la publication source The sigma-1 receptor (S1R) is an endoplasmic reticulum (ER)-resident protein enriched at the mitochondria-associated ER… | International journal of molecular sciences 2026-07-10 11:50:03 | Source |
| Autologous bone marrow mononuclear cell administration for neurologic… Intrathecal infusion of autologous bone marrow stem cells · PMID 41063968 | Sclérose latérale amyotrophique | Traitement symptomatique · Thérapie cellulaire | Publication | PubMed | Voir la publication source Neurological sequelae after traumatic brain injury impair motor and behavioural functions, imposing a heavy burden on p… | Brain communications 2026-07-10 00:23:54 | Source |
| Outcomes of autologous bone marrow mononuclear cell administration co… Intrathecal infusion of autologous bone marrow stem cells · PMID 40442857 | Sclérose latérale amyotrophique | Thérapie cellulaire | Publication | PubMed | Voir la publication source This study evaluated the effectiveness of intrathecal autologous bone marrow mononuclear cell (BMMNC) therapy combined… | Stem cell research & therapy 2026-07-10 00:23:54 | Source |
| BMSC-Derived Exosomes Carrying miR-26a-5p Ameliorate Spinal Cord Inju… Laminectomy and bone marrow stem cells transplantation · PMID 38478142 | Sclérose latérale amyotrophique | Remyélinisation indirecte / réparation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Spinal cord injury (SCI) is a destructive neurological and pathological state that causes major motor, sensory and auto… | Molecular neurobiology 2026-07-10 00:23:53 | Source |
| Spinal cord injury regeneration using autologous bone marrow-derived… Laminectomy and bone marrow stem cells transplantation · PMID 33505602 | Sclérose latérale amyotrophique | Remyélinisation indirecte / réparation · Thérapie cellulaire | Publication | PubMed | Voir la publication source Spinal cord injury (SCI) is an important cause of traumatic paralysis and is mainly due to motor vehicle accidents. How… | World journal of stem cells 2026-07-10 00:23:53 | Source |
| 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. HBI0101 CART · PMID 41428622 | Myasthénie | Ralentissement de la progression · Thérapie génique | Publication | PubMed | Voir la publication source Despite progression-free survival in multiple myeloma (MM) patients extending to 17 years due to contemporary quadruple… | Turkish journal of haematology : official journal of T… 2026-07-10 00:23:45 | Source |
| High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low… HBI0101 CART · PMID 41228344 | Myasthénie | Immunomodulation · Thérapie cellulaire | Publication | PubMed | Voir la publication source : B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has demonstrated substanti… | Cancers 2026-07-10 00:23:45 | Source |
| Adverse Childhood Experiences and Psychological Health in Patients wi… Psychological Health and Adverse Childhood Experiences in Myasthenia Gravis: Online Mental Hea… | Myasthénie | Traitement symptomatique | Publication | PubMed | Voir la publication source : This study examined the prevalence of adverse childhood experiences (ACEs) among patients with myasthenia gravis (MG)… | Healthcare (Basel, Switzerland) 2026-07-10 00:23:43 | Source |
| Long-term Efficacy and Safety of Amifampridine Phosphate (Firdapse) i… Amifampridine Phosphate · PMID 40533232 | Myasthénie | Traitement symptomatique | Publication | PubMed | Voir la publication source Objective To evaluate the efficacy and safety of amifampridine (3,4-diaminopyridine) phosphate in Japanese adults with… | Internal medicine (Tokyo, Japan) 2026-07-10 00:23:42 | Source |
| Treating Castleman disease: insights into the use and efficacy of mon… Rituximab · PMID 42423097 | Cancer · Lupus · Myasthénie · Sclérose en plaques · Myasthénie · Lupu… | Immunomodulation | Publication | PubMed | Voir la publication source Castleman disease (CD) is a rare, heterogeneous group of disorders driven by dysregulated cytokine signaling, particula… | Expert opinion on biological therapy 2026-07-10 00:23:41 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||